Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after b
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... team led by Professor Tadashi ISA, Project Assistant ... Physiological Sciences, The National Institutes of Natural Sciences ... "the double viral vector transfection technique" which can ... combining two new kinds of gene transfer vectors. ...
... ,SALT LAKE CITY, June 14, 2012 In Israel,s Negev ... a toxic "mustard oil bomb" to make the spiny mouse ... the plant has turned a seed-eating rodent into a seed ... by Utah and Israeli scientists. "It,s fascinating that these ...
... International Olympic Committee (IOC) Medical and Scientific Department has ... Centre as an international leader in researching and preventing ... in the Faculty of Kinesiology, will be named one ... sites at a special reception to be held on ...
Cached Biology News:Manipulation of a specific neural circuit buried in complicated brain networks in primates 2Ptooey! 2Ptooey! 3Ptooey! 4IOC recognizes University of Calgary Sports Injury Research Prevention Centre 2
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics ... a life sciences company that develops and commercializes proprietary ... its financial and operational results for the fiscal first ... press release are in Canadian dollars (CAD), unless otherwise ... continued to win new business from our existing customers ...
(Date:2/26/2015)... 26, 2015 DuPont Executive Vice President ... key research advancements and product launches across the Agriculture ... America Merrill Lynch 2015 Global Agriculture Conference. ... grain supplies the last two years, long-term demand for ... of the last decade, when demand for corn and ...
(Date:2/26/2015)... The healthcare landscape is rapidly and radically changing. ... will host its 20 th Anniversary Medical Technologies ... to 10, at the Hilton San Diego Resort and Spa ... This event is a platform for global medical devices, diagnostics, ... and how to succeed in an uncertain future. ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... Sept. 17 MannKind Corporation,(Nasdaq: MNKD ) today ... and Drug Administration to use AFRESA as the trade ... was unveiled today by Alfred Mann,Chairman and Chief Executive ... Conn., location that marked the completion and,dedication of a ...
... Professor And Former Chair Of Psychology Department At Harvard University,Joins ... Leading ... Neurological Testing Company, BERKELEY, Calif., Sept. 17 ... neurological testing for marketing,research, announced that professor Stephen Kosslyn, Ph.D. ...
... based upon Gov. Deval ... Life Sciences Initiative -, LEXINGTON, Mass., Sept. ... Dedication of its new HQ/manufacturing facility, -- WHEN: ... -- WHERE: 44 Hartwell Avenue, Lexington, Mass., RainDance Technologies, ...
Cached Biology Technology:MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 3Neurofocus Appoints Stephen Kosslyn to Its Advisory Board 2RainDance Technologies to Dedicate New Headquarters, Manufacturing Facility in Lexington 2
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
XBP1 Antibody...
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: